Send to

Choose Destination
Atherosclerosis. 2016 Sep;252:182-187. doi: 10.1016/j.atherosclerosis.2016.07.925. Epub 2016 Jul 30.

Dyslipidaemia in the Middle East: Current status and a call for action.

Author information

Department of Clinical Biochemistry, Sultan Qaboos University Hospital, Muscat, Oman. Electronic address:
Heart and Vascular Institute -Cleveland Clinic, Abu Dhabi, United Arab Emirates.
Department of Cardiac Sciences, King Fahad Cardiac Center, College of Medicine, King Saud University, Riyadh, Saudi Arabia.
Laboratory of Biochemistry and Molecular Therapeutics, Faculty of Pharmacy, Saint-Joseph University of Beirut, Beirut, Lebanon.
Baghdad Teaching Hospital, Medical City, Iraqi Board for Medical Specialization, Baghdad, Iraq.
Department of Internal Medicine, Alhada Armed Forces Hospital, Taif, Saudi Arabia.
St Joseph University Faculty of Medicine and Hotel Dieu Hospital, Beirut, Lebanon.
Department of Medicine, Faculty of Medicine, Kuwait University, Kuwait.
Department of Clinical Biochemistry, King Abdulaziz University, Abdullah Sulayman, Jeddah, Saudi Arabia.
Department of Clinical Biochemistry, Sultan Qaboos University Hospital, Muscat, Oman.
School of Medical Sciences, University of New South Wales, Sydney, Australia.


The increase in the cardiovascular disease (CVD)-associated mortality rate in the Middle East (ME) is among the highest in the world. The aim of this article is to review the current prevalence of dyslipidaemia and known gaps in its management in the ME region, and to propose initiatives to address the burden of dyslipidaemia. Published literature on the epidemiology of dyslipidaemia in the ME region was presented and discussed at an expert meeting that provided the basis of this review article. The high prevalence of metabolic syndrome, diabetes, familial hypercholesterolaemia (FH) and consanguineous marriages, in the ME region, results in a pattern of dyslipidaemia (low high-density lipoprotein cholesterol and high triglycerides) that is different from many other regions of the world. Early prevention and control of dyslipidaemia is of paramount importance to reduce the risk of developing CVD. Education of the public and healthcare professionals and developing preventive programs, FH registries and regional guidelines on dyslipidaemia are the keys to dyslipidaemia management in the ME region.


Cardiovascular disease; Dyslipidaemia; Familial hypercholesterolaemia; Guidelines; Middle east; Prevalence

[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center